The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The savings will be fully reinvested to support new product launches and its pipeline across multiple therapeutic areas
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
The inspection was conducted from July 22-25, 2025
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The company is addressing these observations comprehensively
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Subscribe To Our Newsletter & Stay Updated
